Pharmaceutical drug development process
In pharmaceuticals, intellectual property decisions are inseparable from development decisions. The patents you file during early research shape the exclusivity you hold at launch, and the portfolio you build along the way determines whether generic and biosimilar competitors can be kept at bay.
IP-DEAL provides strategic IP guidance throughout the entire drug development lifecycle. We work with pharmaceutical and biotech companies from preclinical research through clinical trials, regulatory submission, and market authorization, making sure your IP position strengthens at every milestone rather than falling behind.
Our team understands the science, the regulatory process, and the competitive dynamics that define this industry. We advise on compound patents, formulation claims, method-of-treatment filings, polymorphs, dosage regimens, and the layered patent strategies that create durable market exclusivity. We also monitor competitor pipelines and patent activity to anticipate challenges before they arrive.
"In drug development, the patents you do not file at the right moment become the ones your competitors use against you."
FAQs
-
Because the window for key filings is narrow, and the consequences of getting it wrong are enormous. A missed filing deadline, an overly narrow claim, or a failure to anticipate a competitor's design-around can cost a company years of market exclusivity and billions in revenue. IP strategy needs to run in parallel with your R&D program from day one.
-
Compound patents cover the active ingredient itself. Formulation patents protect specific dosage forms, delivery mechanisms, or compositions. Method-of-treatment patents cover particular uses of a drug. Additional filings may cover polymorphs, salt forms, metabolites, manufacturing processes, and combination therapies. Together, they form the layered protection that extends effective exclusivity.
-
As early as possible, ideally during the discovery or preclinical phase. Filing a strong compound patent early sets the foundation. As development progresses and you generate new data on formulations, dosing, and clinical outcomes, additional filings should be timed to maximize the remaining patent life at the point of commercial launch.
-
For biosimilar developers, IP strategy focuses on freedom-to-operate analysis, identifying design-arounds for originator patents, and preparing for the patent dance or similar procedures required by regulation. For originator companies, we help build and maintain the patent thickets that protect biological products against biosimilar entry.
-
Regulatory exclusivity, including data exclusivity and market protection periods, works alongside patent protection to define the total period of market exclusivity. We map both regulatory and patent timelines to ensure there are no gaps and that your filings are timed to provide the longest possible combined protection.
-
Yes. At IP Deal, we assess the patent portfolios of acquisition targets and licensing candidates, evaluating claim strength, geographic coverage, remaining patent life, freedom-to-operate risks, and the competitive landscape. Our due diligence reports give you the information you need to negotiate from a position of knowledge.
EXPLORE OUR SERVICES
